Ignite Creation Date:
2024-07-17 @ 10:54 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500689
Status:
COMPLETED
Last Update Posted:
2024-07-15
First Post:
2024-07-08
Brief Title:
To Assess Allisartan IsoproxilSustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
Sponsor:
Shenzhen Salubris Pharmaceuticals Co Ltd
Organization:
Shenzhen Salubris Pharmaceuticals Co Ltd
Study Overview
Official Title:
Efficacy and Safety of Allisartan IsoproxilSustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil A Phase III Multicenter Randomized Double-blind Parallel-controlled 52-week Clinical Study
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxilsustained-release indapamide 240 mg15 mg in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Allisartan Isoproxil 240 mg
Detailed Description:
Allisartan isoproxil is a novel angiotensin receptor blocke available in China for over ten years and has the same active compound EXP3174 with losartan while sustained-release indapamide is a long-standing thiazide-type diuretic The novel single-pill combination of allisartan isoproxil and sustained-release indapamide exerts synergistic antihypertensive effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None